AEON Biopharma, Inc. 8-K

What Happened
AEON Biopharma, Inc. announced on January 12, 2026 that it has posted a corporate presentation to the investor relations section of its website and furnished the presentation as Exhibit 99.1 to a Form 8-K under Regulation FD. The presentation may be used by management in future meetings and includes a slide titled “Forward-Looking Statements” addressing related disclosures.

Key Details

• The Form 8-K was filed January 12, 2026 and furnishes the Corporate Presentation as Exhibit 99.1.
• Presentation is available on AEON’s investor relations website and may be used in future management meetings.
• The presentation includes a “Forward-Looking Statements” slide with risk/forward-looking language.
• The Form 8-K was signed by CEO Robert Bancroft.

Why It Matters
This filing is a disclosure update under Regulation FD, informing all investors that AEON has made updated corporate materials public. Investors should review the presentation for any strategic, program, or pipeline information and note the forward-looking statements and related risk language. The filing does not report earnings, financial results, or management changes.